Compare ALAR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | CGTX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 158.8M |
| IPO Year | 2018 | 2021 |
| Metric | ALAR | CGTX |
|---|---|---|
| Price | $7.83 | $1.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $27.00 | $2.88 |
| AVG Volume (30 Days) | 101.2K | ★ 963.1K |
| Earning Date | 11-26-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $36,305,000.00 | N/A |
| Revenue This Year | $31.17 | N/A |
| Revenue Next Year | $30.14 | N/A |
| P/E Ratio | $49.06 | ★ N/A |
| Revenue Growth | ★ 15.03 | N/A |
| 52 Week Low | $5.45 | $0.22 |
| 52 Week High | $18.00 | $3.83 |
| Indicator | ALAR | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.86 | 44.88 |
| Support Level | $7.20 | $1.46 |
| Resistance Level | $8.30 | $1.76 |
| Average True Range (ATR) | 0.45 | 0.12 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 26.05 | 17.14 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.